NEW YORK, Jan. 14, 2025 ( GLOBE NEWSWIRE ) -- Wolf Haldenstein Adler Freeman & Herz LLP ( "Wolf Haldenstein" ) , a preeminent national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of XBiotech Inc. ( "XBiotech" ) XBIT

AUSTIN, Texas, Dec. 23, 2024 ( GLOBE NEWSWIRE ) -- XBiotech XBIT announced today data that it is halting its clinical program in rheumatological disease while it seeks to understand the outcome from its recently completed Phase II, Double-Blind, Placebo-Controlled, Randomized study in Rheumatoid ...

Equities research analysts at StockNews.com began coverage on shares of XBiotech ( NASDAQ:XBIT - Get Free Report ) in a research note issued to investors on Thursday. The firm set a "sell" rating on the biopharmaceutical company's stock. Shares of XBIT opened at $6.05 on Thursday.

Equities research analysts at StockNews.com initiated coverage on shares of XBiotech ( NASDAQ:XBIT - Get Free Report ) in a research report issued on Wednesday. The brokerage set a "sell" rating on the biopharmaceutical company's stock. NASDAQ:XBIT opened at $5.42 on Wednesday.

Equities researchers at StockNews.com assumed coverage on shares of XBiotech ( NASDAQ:XBIT - Get Free Report ) in a note issued to investors on Tuesday. The brokerage set a "sell" rating on the biopharmaceutical company's stock. Shares of NASDAQ:XBIT opened at $4.30 on Tuesday.